Effect of Polyherbal Formulation on Learning and Memory in Scopolamine Induced Animal Model of Alzheimer’s Disease

Neuroprotective effect of Sumanas

4. Nanjappaiah H M

Department of Pharmacology, BLDEA’s SSM College of Pharmacy and Research Centre, Vijayapur (586103), Karnataka.

Submitted: 01-07-2022
Accepted: 10-07-2022

ABSTRACT

Context: Since there is no any scientific data is available in the management of Alzheimer’s disease by using Sumanas. Hence, the present study is designed to systematically demonstrate the memory enhancing property of Sumanas (SMS) in experimental animal models of Alzheimer’s disease.

Objective: The present study was intended to scientifically validate the effect of Sumanas (SMS), a polyherbal formulation, against scopolamine induced animal model of Alzheimer's disease.

Methods: The memory upgrading action of SMS was established by in vivo (Radial 8 arm maze) process. The Anti-Alzheimer action of Sumanas was evaluated by assessing serum levels of GSH, SOD, total protein, lipid profile and also by histopathological examination of the brain.

Results and Discussion: The outcome of Sumanas on biochemical parameters in Scopolamine induced model exhibits a significant alteration in GSH, SOD, total protein, lipid profile contents were noticed. In the current investigation it was observed that, Sumanas (25, 50, 100 mg/Kg) in a dose dependent manner significantly attenuated the altered biochemical parameters. The results of current research indicated that, the Sumanas got beneficial outcome in the management of Alzheimer’s disease. The statistical results and histopathological observations also confirmed that the Sumanas is a best polyherbal formulation in the management of Alzheimer’s disease due to the presence of various phytoconstituents in it.

Conclusion: The outcome of present investigation indicates that, Sumanas can be suitable as appropriate herbal formulation to treat Alzheimer’s disease models since it has improved the cognitive impairment through memory enhancing property. Which was established by the assessment of different biochemical parameters in scopolamine induced animal model utilized was established by statistical analysis and also confirmed by histopathological report.

Key words: Alzheimer’s disease, Sumanas, Scopolamine, Memory enhancer, cognitive defect.

Key message: The neuroprotective property of sumanas in the management of Alzheimer’s disease.

I. INTRODUCTION

Alzheimer’s disease (AD) is a degenerative brain disease, most general form of dementia that typically begins in late middle age or in old age which brings about reformist cognitive decline, bewilderment, weakened reasoning, and changes in character, temperament and checked histological changes by the degeneration of cerebrum neurons particularly in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.

The disease was named after Dr. Alois Alzheimer. In 1906, Dr. Alzheimer observed changes in the brain tissue of a lady who had died of surprising psychological sickness. Her indications included cognitive decline, language troubles, and flighty conduct. After she passed on, he analyzed her cerebrum and discovered numerous strange bunches (presently called amyloid plaques) and tangled heaps of filaments (presently called neurofibrillary, or tau, tangles).

These plaques and tangles in the brain are as yet thought to be a portion of the primary highlights of AD. Another component is the deficiency of associations between nerve cells (neurons) in the cerebrum. Neurons send messages...
between various pieces of the brain, and from the cerebrum to muscles and organs in the body. Numerous other complex brain changes are thought to assume a part in Alzheimer’s as well. This harm at first seems to happen in the hippocampus, the piece of the cerebrum fundamental in shaping recollections. As neurons pass on, extra pieces of the mind are influenced. By the last phase of Alzheimer’s, harm is boundless, and brain tissue has contracted effectively.

Presently, the management of Alzheimer’s disease is non acceptable and allopathic drugs for management of Alzheimer’s disease is not sufficient and not much benefited so in this concern, natural products probably signify an wonderful source to develop safe and effective agents for management of AD. The polyherbal formulation, Sumanas (SMS) used by Ayurvedic practitioner to treat cognitive decline cases. The component of this includes, Brahmi, Shankhpushpi, Jatamansi, Sarpagandha, Parasika Yavani and Vacha. The Bramhi (Bacopa monnieri), Shankhpushpi (Clitoria ternatea), Jatamansi (Nardostachys (jatamansi), Sarpagandha (Rauwolfia serpentina), Parasika Yavani (Hyoscyamus niger), Vacha (Acorus calamus)reported to possess memory enhancing activity in AD.

However in any case, no scientific data is available for the management of Alzheimer’s disease by using Sumanas. Hence, the present study is designed to systematically demonstrate the memory enhancing property of Sumanas (SMS) in experimental animal models of AD.

### II. METHODOLOGY

- **Materials and methods:**
  - **Source of data:** All the data collected from the animal experiments and standard parameters for the study.
  - **Methods of collection of data**
  - **Collection of SMS**
    - SMS powder collected from pavaman Pharmaceuticals, Vijayapur, Karnataka, India
  - **Method for the evaluation of SMS tablet for anti-Alzheimer activity**

**Model 2: Scopolamine induced Alzheimer’s disease model:**

The animals divided into different groups:-

<table>
<thead>
<tr>
<th>Groups</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>Untreated-distilled water orally for 15 days</td>
</tr>
<tr>
<td>Control</td>
<td>Received scopolamine (2mg/kg i.p) for 15 days.</td>
</tr>
<tr>
<td>Standard</td>
<td>Received scopolamine (2mg/kg i.p) and Rivastigmine (2mg/kg orally) for 15 days.</td>
</tr>
<tr>
<td>Treated</td>
<td>Received scopolamine (2mg/kg i.p) and Low dose (25mg/kg) of SMS orally for 15days.</td>
</tr>
<tr>
<td>Treated</td>
<td>Received scopolamine (2mg/kg i.p) and Moderate dose (50mg/kg) of SMS orally for 15days.</td>
</tr>
<tr>
<td>Treated</td>
<td>Received scopolamine (2mg/kg i.p) and High dose (100mg/kg) of SMS orally for 15days.</td>
</tr>
</tbody>
</table>

**Radial 8 Arm Maze Test**

- **In radial arm maze the study of spatial reference and working memory process in rats were assessed.**
- **Apparatus:**
  - It is a wooden elevated 8 arm radial maze with arms extending from a central platform having a diameter of 20 cm.
  - Each arm is 56 cm long and 5 cm wide with height of 2 cm. Food pellets which serve as reward at the end of the arm.
Animals are trained daily to collect food pellets. The session terminates after 8 choices and the rat has to obtain the maximum no. of rewards with least no of errors. The baited arms- 2, 4, 6, 8 (reference memory error) and non baited arms-1, 3, 5, 7 (working memory error) are arranged for further analysis of cognitive performance of the animal.

Biochemical Estimations:-

i) Preparation of brain homogenate for the estimation of,
A. SOD
B. Protein
C. GSH
1) Dissection: The rats are decapitated; brains are removed quickly and placed in ice-cold saline. Frontal cortex, hippocampus and septum (and any other regions of interest) are quickly dissected out on a petridish chilled on crushed ice.
2) A homogenate (10% w/v) is prepared in 0.1M phosphate buffer (pH 7.4). The homogenate was centrifuged at 10,000 rpm for 15 minutes and aliquots of supernatant was separated and used for biochemical estimation.

A. Superoxide dismutase (SOD): The SOD activity (U/mg of protein) was calculated by using the standard plot.
B. Protein: The protein concentration in samples was determined.
C. Glutathione (GSH): The GSH activity (U/mg of protein) was calculated by using the standard plot.

ii) Determination of serum Lipid profile
A. Total Cholesterol
B. Triglycerides
C. High density lipoprotein (HDL) cholesterol

D. LDL-cholesterol

Statistical analysis: All the data was expressed in mean ± SEM. The significance level of mean between control and treated animals for different parameters was determined by one way ANOVA followed by Dunnett’s Multiple Comparison Test. P value < 0.05 was considered as statistically significant.

Histopathological studies:-
The brains of all the animals were fixed with 10% formalin and embedded in paraffin wax and cut into longitudinal section of 5 μm thickness. The sections were stained with haemotoxylin and eosin dye for histopathological observation.

III. RESULTS

Anti-Alzheimer’s Activity:-

Scopolamine induced Alzheimer’s disease model:-

In the present model, control animals showed increased level of LDL, TC, TG and total protein content whereas SOD, GSH and HDL levels were decreased. Animals pretreated with SMS at different doses significantly restored these altered biochemical parameters in a dose dependent manner.

The data thus obtained of SMS was comparable with the standard drug (Rivastigmine 2mg/kg). The results were shown in Table-1. 2. Hence the memory enhancing property of SMS polyherbal formulation in graded doses (25, 50 and 100 mg/kg) was found to be almost equal potent to the reference slandered drug, Rivastigmine in this model.

<table>
<thead>
<tr>
<th>Groups</th>
<th>SOD (U/mg of protein)</th>
<th>Total protein (U/mg of protein)</th>
<th>GSH (nmoles/mg of protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>6.8±0.31</td>
<td>0.79±0.12</td>
<td>18.9±0.03</td>
</tr>
<tr>
<td>Control</td>
<td>2.8±0.21</td>
<td>1.03±0.11</td>
<td>14.3±0.06</td>
</tr>
<tr>
<td>Standard</td>
<td>6.4±0.26***</td>
<td>0.71±0.23***</td>
<td>18.2±0.05***</td>
</tr>
</tbody>
</table>
**Table 2**

Effect of SMS on lipid profile in scopolamine induced AD model.

<table>
<thead>
<tr>
<th>Groups mg/kg</th>
<th>TC</th>
<th>TG</th>
<th>HDL</th>
<th>LDL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>113.39±0.25</td>
<td>61.78±0.42</td>
<td>58.66±0.32</td>
<td>70.94±1.31</td>
</tr>
<tr>
<td>Control</td>
<td>143.11±0.65*</td>
<td>82.69±1.11a</td>
<td>49.23±0.87a</td>
<td>103.86±1.31a</td>
</tr>
<tr>
<td>Standard</td>
<td>120.78±1.64**</td>
<td>60.04±1.87**</td>
<td>59.21±0.84**</td>
<td>72.44±0.68***</td>
</tr>
<tr>
<td>SMS(25mg)</td>
<td>132.21±2.12*</td>
<td>75.01±1.73*</td>
<td>50.43±1.12*</td>
<td>89.23±0.64*</td>
</tr>
<tr>
<td>SMS(50mg)</td>
<td>129.15±2.91**</td>
<td>69.18±1.65**</td>
<td>53.76±0.89*</td>
<td>81.01±1.31**</td>
</tr>
<tr>
<td>SMS(100mg)</td>
<td>123.18±2.14**</td>
<td>63.79±1.14**</td>
<td>59.32±0.88**</td>
<td>76.76±0.98***</td>
</tr>
</tbody>
</table>

All the values are expressed as mean±SEM, n=6, *p<0.05, **p<0.01, as compared to sham group; and *p<0.05, **p<0.01, ***p<0.001, (One way Analysis of Variance [ANOVA] followed by Dunnett’s test for multiple comparisons) as compared to control group.

Note: SMS: Sumanas tablet; TC: Total Cholesterol; TG: Triglyceride; HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein.

Effect of SMS on histopathological studies in scopolamine induced model:-
Histopathological profile:

In control group, the animals (Plate-B) showed severe changes in degeneration and pyknosis in hippocampal neurons and gliosis with increased infiltration of neutrophils. And moderate changes observed in congestion and hippocampal oedema with increased neuronal degeneration in cerebral cortex, when compared sham operated group (Plate-A).

In treated groups, the animals (Plate-D, E and F) showed decreased infiltration of neutrophils and infraction size, reduced
intracellular space, increased density of cells and regained normal architecture and moderate necrosis was observed in striatum region of brain as compared to control group.

High dose of SMS (100 mg/kg - Plate F) showed significant improvement in striatum region of brain which can be comparable with standard (Rivastigmine) group (Plate-C).

IV. DISCUSSION

Alzheimer’s disease is one type of brain disease which is also known as neurodegenerative disease with cognitive defects and memory impairment. At the beginning stage the persons with AD won’t experience any symptoms but later slowly brain start changing then the symptoms are visible such as loss of memory and problems in communication. These symptoms occur because of severe damage in neurons (nerve cells). Over the long term, manifestations will in general increment and begin meddling with person’s capacity to perform regular exercises, now the individual is said to have dementia because of AD. The AD patient fails to perform routine activities which he did earlier in his life very easily that used to be core to the individual’s identity, such as combing, cleaning, washing clothes, operating phone and planning family events or participating in sports. Finally, neurons in parts of the cerebrum that empower an individual to do fundamental real capacities, like strolling and gulping, are influenced. Individuals in the last phases of AD bed-bound and need nonstop consideration therefore over all it was confirmed that, the Alzheimer’s disease is mortal and dangerous.

Scopolamine is famous anti cholinergic drug which blocks the functions of cholinergic system through muscarinic receptors hence known asanti muscarinic agent. And often it is used as a standard drug to produce cognitive impairment in experimental animals. Especially when scopolamine administrated intraperitoneally that leads to cholinergic dysfunction and impaired cognition in rats.

It was reported that, scopolamine cause memory impairment by causing oxidative stress. Previously, it was used in the conditions like child birth in obstetrics to induce twilight state and amnesia. Further specialists detailed that, scopolamine caused decline in choline acetyltransferase (the compound answerable for combination of acetylcholine) in cortex of AD patients, hence scopolamine used in cognitive research in AD patients. Scopolamine is also induced cerebral blood flow and glucose metabolism, which was studied with the help PET (Positron Emission Tomography).

Research reports also indicated that, cholinergic system plays vital role in balancing the memory function. The loss of memory and disorientation of AD was mainly due to decrease in central cholinergic system and Blockade of its functions hence loss of cholinergic neurons in brain areas like hippocampus, cortex, nucleus basal of Meynert leads to loss of memory and learning. A cognitive deficit was mainly associated with reduction in cholinergic activity. Researchers reported that, scopolamine non-selectively occludes the adhesion site of Ach muscarinic receptors in cerebral cortex which alters the level of acetylcholine and induce learning and memory defects in dose dependent manner. Scopolamine can be either infused in amygdala (72 μg/ 219 0.5 μl at a rate of 1 μl/min) or given by intraperitoneal route (0.3 or 0.5 mg/kg) for cognitive dysfunction and memory impairment. This Scopolamine induced animal model successfully impairs the memory which causes the defects in cognition therefore it is one of the most widely used models because not having any difficult surgical procedures is not required.

Current study showed that, intraperitoneal administration of scopolamine caused significant loss in learning and memory associated with decreased level of GSH, SOD because of increased generation of free radicals and reduced activity of glutathione system in combating oxidative stress. Increased total protein level in the brain is due to an enhanced production in neurons associated with the progression of AD and decreased level of HDL while increase in LDL, TC, TG in lipid profile analysis because change in lipid metabolism and increased synthesis of amyloid –β protein leads to increase in cellular protein and cholesterol level in brain which responsible for AD. But these elevated levels in lipid profile were successfully restored by lower dose, moderate dose (50mg/kg) and high dose (100mg/kg) of SMS comparable with standard drug rivastigmine (2mg/kg).

Rivastigmaine is a carbamate-based, reversible, noncompetitive inhibitor of AChE hence it may acts by selectively inhibiting AChE enzyme which leads to enhance the cholinergic function this increases the availability of Ach therefore used as the standard drug for experimental animals in AD but exact mechanism is unknown.

SMS polyherbal formulation belongs to the group of Bramhi (Bacopa monnieri), Shankhpushpi (Clitoria ternatea), Jatamansi

showing the enhancement of learning and memory by SMS.

V. CONCLUSION

The present investigation demonstrated the neuroprotective property of Sumanas by improving the cognitive defects induced by scopolamine due to its memory enhancing property. The outcomes of the present study scientifically authenticate the traditional use of Sumanas as a polyherbal formulation for the management of Alzheimer’s disease.

VI. ACKNOWLEDGEMENT

I would like to acknowledge the incredible help provided by the cooperative and supportive staff of the pharmacology department and principal of the B.L.D.E.A’s SSM College of Pharmacy and Research Centre, vijaypur. I would also like to thank my friends and family who supported me and offered deep insight into the study.

CONTRIBUTORS’ FORM

MANUSCRIPT TITLE: Effect of Polyherbal Formulation on Learning and Memory in Scopolamine Induced Animal Model of Alzheimer’s Disease

I/we certify that I/we have participated sufficiently in the intellectual content, conception and design of this work or the analysis and interpretation of the data (when applicable), as well as the writing of the manuscript, to take public responsibility for it and have agreed to have my/our name listed as a contributor. I/we believe the manuscript represents valid work. Neither this manuscript nor one with substantially similar content under my/our authorship has been published or is being considered for publication elsewhere, except as described in the covering letter. I/we certify that all the data collected during the study has been analyzed and presented in this manuscript and no data from the study has been or will be published separately. I/we attest that, if requested by the editors, I/we will provide the data/information or will cooperate fully in obtaining and providing the data/information on which the manuscript is based, for examination by the editors or their assignees. Financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this paper have been disclosed in the cover letter.
Sources of outside support of the project are named in the cover letter.

I/We hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership, including any and all rights incidental thereto, exclusively to this journal, in the event that such work is published by the journal. The journal shall own the work, including 1) copyright; 2) the right to grant permission to republish the article in whole or in part, with or without fee; 3) the right to produce preprints or reprints and translate into languages other than English for sale or free distribution; and 4) the right to republish the work in a collection of articles in any other mechanical or electronic format.

We give the rights to the corresponding author to make necessary changes as per the request of the journal, do the rest of the correspondence on our behalf and he/she will act as the guarantor for the manuscript on our behalf.

All persons who have made substantial contributions to the work reported in the manuscript, but who are not contributors, are named in the Acknowledgment and have given me/us their written permission to be named. If I/we do not include an Acknowledgment that means I/we have not received substantial contributions from non-contributors and no contributor has been omitted.

CHECKLIST

Manuscript Title: Effect of Polyherbal Formulation on Learning and Memory in Scopolamine Induced Animal Model of Alzheimer’s Disease

Covering letter
Signed by all contributors
✓ Previous publication / presentations mentioned
✓ Source of funding mentioned
✓ Conflicts of interest disclosed

Authors
✓ Middle name initials provided
✓ Author for correspondence, with e-mail address provided
✓ Number of contributors restricted as per the instructions
✓ Identity not revealed in paper except title page (e.g. name of the institute in material and methods, citing previous study as ‘our study’, names on figure labels, name of institute in photographs, etc.)

Presentation and format
☐ Double spacing
☐ ✓ Margins 2.5 cm from all four sides
✓ Title page contains all the desired information (vide supra)
✓ Running title provided (not more than 50 characters)
✓ Abstract page contains the full title of the manuscript
✓ Abstract provided (not more than 150 words for case reports and 250 words for original articles)
✓ Structured abstract provided for an original article
✓ Key words provided (three or more)
✓ Key messages provided
✓ Introduction of 75-100 words
✓ Headings in title case (not ALL CAPITALS, not underlined)
✓ References cited in superscript in the text without brackets
✓ References according to the journal’s instructions.

Language and grammar
✓ Uniformly British English
✓ Abbreviations spelt out in full for the first time
✓ Numerals from 1 to 10 spelt out
✓ Numerals at the beginning of the sentence spelt out

Tables and figures
✓ No repetition of data in tables/graphs and in text
☐ Actual numbers from which graphs drawn, provided
✓ Figures necessary and of good quality (colour)
✓ Table and figure numbers in Arabic letters (not Roman)
✓ Labels pasted on back of the photographs (no names written)
✓ Figure legends provided (not more than 40 words)
☐ Patients’ privacy maintained (if not, written permission enclosed)
✓ Credit note for borrowed figures/tables provided

Contribution Details
<table>
<thead>
<tr>
<th>Concepts</th>
<th>Desai Shraddha¹</th>
<th>Hugar Shivakumar ¹</th>
<th>Nanjappaiah H M¹</th>
<th>Patil Virupanagouda*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Definition of intellectual content</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Literature search</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Clinical studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experimental studies</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Data acquisition</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Data analysis</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Statistical analysis</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Manuscript preparation</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manuscript editing</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Manuscript review</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Guarantor</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

**REFERENCE**


